CD274 and non-small cell lung carcinoma: An 83 y/o male with advanced poorly differentiated NSCLC and positive PD-L1 expression (tumor proportion score [TPS] = 70%) had an obvious decrease in the plasma circRNA levels after receiving nivolumab, and significant improvement of symptoms was also noted (Figure 6D).